Case Study 2: The Price of Life

A Note on This Case

The pharmaceutical pricing controversy examined in this case study is a composite — a fictional company and drug constructed to reflect the documented pattern of pricing decisions that has generated intense public and academic controversy over the past two decades. The company is NovaCure Pharmaceuticals. The drug is Cardinex. The pattern is real.

Background: The Drug, the Company, the Price

Cardinex is a treatment for hypertrophic cardiomyopathy, a genetic heart condition that affects approximately 1 in 500 people and is the leading cause of sudden cardiac death in young athletes. For most patients, the condition is manageable with existing medications and lifestyle modifications. But for a subset of patients — those with what cardiologists call "obstructive" forms of the disease — the prognosis is significantly worse without aggressive intervention.

For two decades, the standard of care for these patients was surgery or a procedure called septal ablation, both of which carry significant risk. Cardinex, a small-molecule drug that reduces the mechanical obstruction without surgery, represented a genuine therapeutic advance. In clinical trials, it reduced symptoms significantly and improved quality of life measures substantially.

NovaCure, a mid-sized pharmaceutical company, did not develop Cardinex from scratch. It licensed the compound from a university research lab — where it had been developed with significant federal grant funding — and invested approximately $800 million in the clinical trials and regulatory work required to bring it to market. This investment was real. Clinical trials are expensive, slow, and uncertain; many compounds that look promising in early trials fail in later ones.

NovaCure received FDA approval for Cardinex. It priced the drug at $96,000 per year.

The Immediate Effects

At $96,000 per year — $8,000 per month — Cardinex was beyond the reach of most uninsured patients. Private insurers covered it, but often only after extensive prior authorization processes that required patients to demonstrate that they had tried and failed other treatments. Medicaid coverage varied by state. Medicare covered it, but with cost-sharing requirements that produced annual out-of-pocket costs of several thousand dollars for patients on fixed incomes.

A study by patient advocacy groups eighteen months after launch found that approximately 34% of patients who had been prescribed Cardinex by their cardiologist had not filled the prescription, primarily due to cost. Among uninsured patients, the non-fill rate was 61%.

NovaCure established a patient assistance program providing free or reduced-cost Cardinex to low-income patients who met eligibility requirements. Approximately 12% of eligible patients successfully enrolled in the program; the enrollment process required documentation and reapplication every six months.

The Company's Defense

NovaCure's CEO, in a widely circulated interview, made the following arguments:

The innovation argument: "We took on enormous financial risk to bring this drug to patients. The $800 million we spent on trials and regulatory work is not guaranteed to produce an approved drug — most compounds fail. We need to price successful drugs to recoup the costs of the failures as well. If we can't earn a return on our investment, we can't fund the next generation of innovation."

The value argument: "Cardinex provides enormous value to patients. The cost of the alternative — surgery with all its risks and recovery time — is comparable or higher when you account for hospital costs, lost productivity, and complications. We're pricing to value."

The access argument: "We have a robust patient assistance program. No patient should be denied access due to cost. We're committed to working with patients who need help."

The market argument: "The market determines what drugs cost. Payers — insurance companies and pharmacy benefit managers — negotiate prices aggressively. If our price were truly unreasonable, payers wouldn't cover the drug."

Applying the Frameworks

Consequentialist Analysis

The consequentialist question is: what are the aggregate effects of Cardinex being priced at $96,000 per year, compared to alternative pricing scenarios?

The innovation defense, examined

The innovation argument is the most intellectually serious defense of high pharmaceutical prices, and it deserves careful engagement rather than dismissal.

It is true that pharmaceutical development is expensive, uncertain, and risky. It is true that without the expectation of significant profit, investors would not fund pharmaceutical development at current levels. It is true that many drugs that improved or saved lives would not have been developed if the companies that developed them could not earn a substantial return.

But the consequentialist calculus is more complex than this argument acknowledges.

First, there is the question of public subsidy. Cardinex was developed initially with federal research funding — taxpayer money. The basic science that made the drug possible was conducted at a university, funded by NIH grants. NovaCure paid to license the compound and conduct clinical trials; it did not fund the underlying research from zero. A strict accounting of who took what financial risk, and who is entitled to what return, would have to grapple with the public's role in funding the basic science.

Second, there is the question of access effects. The 34% non-fill rate documented by patient advocates represents patients who were prescribed Cardinex by their cardiologists and chose not to take it because they could not afford it. These are not hypothetical harms; they are documented failures of treatment that have health consequences. A consequentialist analysis that counts the benefits of Cardinex to the patients who can afford it, but does not count the harms to the 34% who cannot, is incomplete.

Third, there is the question of what level of profit is required to sustain pharmaceutical innovation, and whether $96,000 per year per patient exceeds that level. Pharmaceutical companies consistently rank among the most profitable industries in the economy, with profit margins that exceed most other sectors including technology. It is not obvious that innovation would cease if pharmaceutical prices were set at levels that produced, say, 20% rather than 40% profit margins.

The aggregate calculus

A fully honest consequentialist accounting would need to include: the health gains to patients who access Cardinex; the health losses to patients who cannot; the downstream effects on families and caregivers; the effect of pricing norms on future pharmaceutical innovation; the effect of those norms on public trust in the pharmaceutical industry; and the opportunity cost of healthcare dollars spent on Cardinex that might otherwise fund other health interventions.

This is not a calculation that yields a clean answer. But a consequentialist analysis that takes seriously all these considerations is less favorable to the $96,000 price than NovaCure's public defense suggests.

Kantian Analysis

The Kantian analysis focuses on how NovaCure is treating the patients who need Cardinex.

The "value-based pricing" argument — pricing to what the treatment is worth to patients — is revealing in Kantian terms. What does it mean to price a drug according to its value to a patient with a serious heart condition? It means using the patient's need — their vulnerability, their desire to live — as the mechanism by which the price is set. The more desperate the patient, the higher the price can be set. This is precisely the structure of treating a person as a means: exploiting their situation for profit.

The philosopher Michael Sandel draws a distinction between market exchange and other forms of human relationship, arguing that when we price things according to what desperate people will pay, we corrupt the relationship that the exchange is supposed to embody. Healthcare, on this view, is not supposed to be a straightforward market transaction; it is supposed to be a relationship in which one party with expertise and resources helps another party in need. Pricing that relationship according to the vulnerability of the patient turns the relationship into something else.

The patient assistance program is worth examining through the Kantian lens. NovaCure offers free or reduced-price Cardinex to low-income patients who complete a lengthy application process and re-apply every six months. This is marketed as evidence of the company's commitment to access. But the program is discretionary — it can be scaled back or eliminated at any time. It requires patients to prove their poverty, repeatedly. And it covers only 12% of eligible patients. A Kantian analysis of genuine respect for persons would ask whether this program treats patients as individuals with dignity, or as objects of a PR exercise.

Justice Analysis

The Rawlsian framework is perhaps the most powerful analytical tool for pharmaceutical pricing, because it directly addresses the distributional question.

From behind the veil of ignorance: if you did not know whether you would be a NovaCure shareholder, a patient with obstructive hypertrophic cardiomyopathy and good insurance, a patient with the same condition and no insurance, or a taxpayer who funded the basic research through NIH grants — what pricing rules would you choose?

A few observations from behind the veil:

You would almost certainly not choose a system in which a patient who was prescribed a drug by their physician had a 34% chance of not receiving it due to cost. Whatever your position in society, the possibility of being that patient — diagnosed with a serious condition, prescribed an effective treatment, unable to fill the prescription — is a risk you would want to minimize.

You would probably want some relationship between price and the public investment that helped create the drug. If taxpayers funded the basic science, the system that lets a company capture most of the economic value of that science without sharing it with the public funder has something to explain.

You would want an innovation system that continued to develop new drugs — but you would also want to know that the prices you would pay for those drugs bore some reasonable relationship to the actual costs of development rather than to the maximum the market would bear.

The difference principle applied

Rawls's difference principle asks: are the people who are worst off in this arrangement better off than they would be under a feasible alternative arrangement?

The people worst off in the current pharmaceutical pricing system are patients who need life-improving or life-saving drugs that they cannot afford. Under alternative arrangements — reference pricing tied to development costs, mandatory licensing for drugs developed with significant public subsidy, differential pricing based on ability to pay — would these patients be better off?

The available evidence from countries that have adopted alternative pricing systems suggests that patients in those systems generally do have better access to essential medicines, at no obvious cost to innovation rates. This is contested empirical terrain, but it is terrain that a Rawlsian analysis demands we examine rather than assume.

Virtue Ethics Analysis

What does NovaCure's pricing decision reveal about the company's character?

The most revealing data point is the patient assistance program. A company of genuine integrity, confronted with a 34% non-fill rate among prescribed patients, would treat that figure as evidence of a failure that requires remediation — not as evidence that the program is working. It would ask: how do we design a system that ensures every patient who is prescribed this drug can access it, not how do we minimize the PR damage from our pricing decision?

The difference between those two questions is a difference in orientation — toward patients, or toward shareholders — that reflects institutional character.

This is not a claim that pharmaceutical companies have no legitimate interest in profitability. They do. The virtue ethics tradition does not require selflessness; it requires that the pursuit of legitimate self-interest be bounded by attention to the interests of others. The question is whether NovaCure's pricing decision reflects that balance, or whether it reflects an institution that has determined that patient access is a marketing problem rather than a moral obligation.

Complicating the Analysis: The Hard Questions

What If the Innovation Argument Is Right?

Suppose the innovation argument is stronger than the Kantian and Rawlsian critiques suggest. Suppose it is true that if pharmaceutical prices were set at levels that allowed only modest profits, the industry would substantially reduce investment in new drug development, and that the long-run consequence would be significantly fewer new treatments for cancer, heart disease, neurological conditions, and infectious disease.

This is an empirical question, and the evidence is genuinely mixed. But suppose the evidence supported it clearly. Would this change the ethical analysis?

From a consequentialist standpoint: if lower drug prices now meant significantly fewer effective drugs in the future, and if the long-run health gains from future innovation outweigh the short-run harms from current inaccessibility, the case for high pharmaceutical prices strengthens. The difficulty is that this argument has been used to justify essentially any pricing decision, regardless of evidence.

From a Kantian standpoint: even if high prices serve the future social good, treating current patients' vulnerability as the mechanism for setting prices remains problematic. The Kantian argument is about the character of the relationship, not just the consequences.

From a justice standpoint: a system that harms the worst-off now in order to benefit future generations needs to be evaluated carefully. Future people cannot advocate for themselves; current patients can, and do.

Who Has the Obligation to Fix This?

If NovaCure's pricing is ethically problematic, who has the obligation to change it?

The company has an obligation: it is the direct actor, and it has the most direct power to change the outcome.

Regulators have an obligation: the current legal framework allows pharmaceutical companies to charge essentially any price the market will bear. Changing this requires political action.

Insurance companies and pharmacy benefit managers have significant power and significant obligations: they negotiate drug prices and design coverage policies that determine who can access drugs.

Physicians have obligations: prescribing a drug without attention to whether the patient can afford it is not ethically neutral.

Patients and the public have some role: political pressure and public opinion have affected pharmaceutical pricing decisions in documented cases.

The interesting observation is that responsibility is distributed across a system, and the distribution of responsibility tracks the distribution of power. This is not a coincidence.

Discussion Questions

1. NovaCure's CEO argues that the patient assistance program ensures that "no patient should be denied access due to cost." Given that only 12% of eligible patients successfully enrolled, evaluate this claim. What would genuine commitment to access require?

2. Cardinex was initially developed with federal research funding before NovaCure licensed and developed it commercially. Does the public subsidy of basic research create any obligation on the company's part regarding pricing or access? Apply both Kantian and Rawlsian frameworks.

3. Several countries have "compulsory licensing" laws that allow generic manufacturers to produce drugs without the patent holder's consent when the patent holder's pricing creates a public health emergency. Apply the ethics of civil disobedience framework (Chapter 8) to this scenario: is compulsory licensing an ethical response to pharmaceutical pricing that creates significant public health harm?

4. Suppose you are a portfolio manager at a pension fund that holds NovaCure stock. You are responsible for the retirement security of thousands of workers. You have concerns about NovaCure's pricing practices. What do you do? Apply at least two frameworks in your answer.

5. The pharmaceutical industry argues that the U.S. high-price market effectively subsidizes global pharmaceutical innovation — that American patients pay high prices partly to fund the research that benefits patients worldwide who pay much less. Evaluate this argument. Is it morally relevant? Does it change the ethical analysis of any particular company's pricing decisions?